Clinically significant benefit derived from botulinum toxin for urinary incontinence

Chris Chapple. Joab Patients with urinary urgency , whose symptoms are not adequately treated with anticholinergic therapy were recruited patients were randomized to treatment with Botox 50U, 100U, 150U, 200U and 300U or placebo was given this intradetrusor injections. .Patients were followed for 36 weeks after treatment with assessments, log book to 7 days after the residual urine volume of zero , health-quality of life questionnaires and urodynamics.

Treatment options for idiopathic OAB in patients not adequately managed by anticholinergic therapy is limited, it is very invasive, expensive or of limited effectiveness. BOTOX can provide an effective minimally invasive treatment. Prof. Chris Chapple and his team conducted the first large, double-blind, placebo-controlled, dose-depth study to systematically evaluate the benefit / risk of the use of BOTOX in a wide range Joab doses. The results were presented at the sixtieth anniversary of the EAU Congress in Barcelona

One expert called the study only a small step on the road for more personalized treatments for patients. I do not know if this is enough to push people to use it, said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York.

Dose-response was identified in the parameters of efficiency, but a minimum UUI analysis showed greater efficacy at higher doses to doses of Botox HRQL measures 150U and many have shown minimal additional benefit over the 100U.